Skip to content

GLP-1 drugs: the cost today against the benefit tomorrow

Bank of America says it spends $250 million a year on GLP-1 medications for employees. Every employer is now facing a smaller version of the same question.

A parent and toddler hold hands as they walk along the shoreline toward a low setting sun
Photo: Unsplash

$250 million a year on GLP-1 medications. That is what Bank of America says it is spending on these drugs for its employees, according to CNBC.

It sounds like an incredible amount of money, and it raises a real question for every employer.

The question

If GLP-1s improve obesity, diabetes and other chronic conditions, could spending more today create healthier employees and lower healthcare costs over the long term?

We do not know that answer yet.

What we do know

  • Marsh estimates growing GLP-1 use accounts for about one percentage point of the projected 2027 increase in employer health costs.
  • In KFF's 2026 survey, 18% of firms with 200 or more workers covered GLP-1s for weight loss, usually with conditions attached.
  • Almost a third of employers that cover them said the drugs had a significant effect on their prescription spending.

Options employers are using

  • Cover the drugs for diabetes and set clinical criteria for weight loss.
  • Require participation in a weight management program.
  • Review the pharmacy contract so you know what you are paying net of rebates.
  • If you are self funded, look at the claims data before deciding, not after.

With healthcare costs continuing to rise, this is going to be one of the biggest benefits conversations of the next several years.

What is the right balance between the cost today and the potential benefit tomorrow?

A family walking hand in hand through a green field

Get started

Tell us when you renew. We will show you what we would do differently.

A 20-minute conversation with a benefits advisor. No census required to start, and switching takes one signed letter.